Glomerulonephritis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

March 8, 2011 - PRLog -- GlobalData estimates that the global Glomerulonephrits (GN) market was valued at $258m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 5.7% to reach $382m by 2017. This modest growth forecast is primarily attributed to a strong pipeline landscape. The existing market is strong. Very few products are approved for some types of GN such as membranoproliferative GN, minimal change GN and cresentic GN. The market is characterized by several off-label drugs and generics that treat the symptoms of the condition. Antihypertensive agents, immunosuppressants, corticosteroids and antibiotics are the most commonly employed therapies to treat the condition symptomatically. There is a lack of disease modifying agents in the market.

GlobalData has found that the GN market has moderate unmet needs, which implies that the market is not well served by the current products and that there is less scope for new entrants. GN therapies are largely targeted at treating the symptoms of the condition. The market is dominated by generics and off-label medications which include antihypertensive agents, immunosuppressive agents, corticosteroids, and antibiotics. In summary, the GN market is expected to be a relatively less open market for new entrants until 2017 with few opportunities for value capture.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

A strong pipeline with eight molecules in various phases of clinical development, including seven first-in-class molecules, will drive the market in the forecast period. Some of these first-in-class molecules have a distinct advantage over the currently marketed products for GN in terms of providing better immunosuppression or reno protection. The pipeline includes rennin inhibitors, anti CD20 antibody, mammalian Target of Rapamycin (mTOR) activator inhibitors, IgG immunoglobulins, immunosupressants and Transforming Growth Factor β (TGFβ) antagonist. Most of the clinical trials are being sponsored by universities and are not expected to affect the future GN therapeutic market significantly. Due to this, only a few branded products are expected to enter the GN market.

GlobalData, the industry analysis specialist, has released its new report, “Glomerulonephritis Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global glomerulonephritis therapeutics market. The report identifies the key trends shaping and driving the global glomerulonephritis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global glomerulonephritis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Glom...

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com            
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData's Report Store features thousands of high quality research reports across a broad range of industries. The reports draw on in-depth primary and secondary research, databases of proprietary in house data and high quality analysis from our expert teams. Data and analysis at the company, country and industry level includes competitors, valuations, trends, forecasts and analytics. Please feel free to browse our reports via the industry tabs below or alternatively contact us if you have any specific data requests or queries.